{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:06:25Z","timestamp":1775149585041,"version":"3.50.1"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"unspecified","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjonc"],"accepted":{"date-parts":[[2026,3,11]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate sex differences in baseline clinical characteristics, analgesic response, safety profiles and treatment variations among cancer patients initiating WHO step III opioid therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      This post hoc analysis used data from a four-arm, multicentre, randomised, comparative, superiority phase IV trial in cancer patients with moderate-to-severe pain requiring WHO step III opioids. The study was conducted across 44 specialist palliative care centres in Italy. Overall, 498 patients were evaluated, including 277 men (55.6%) and 221 women (44.4%). Eligible participants had locally advanced or metastatic tumours and persistent moderate-to-severe pain. Patients were centrally randomised (1:1:1:1) to morphine, oxycodone, buprenorphine or fentanyl around the clock. Follow-up lasted 28 days, with assessments on days 1 day, 3 days, 7 days, 14 days, 21 days and 28 days. Physicians could adjust opioid doses, add adjuvants or switch opioids as clinically indicated. Adverse drug reactions (ADRs) were recorded. Baseline assessments included oncological history, comorbidities, Karnofsky performance status and self-reported psychological status. Pain intensity (PI) was measured on a 0\u201310\u2009Numerical Rating Scale for average PI (API) and worst pain over the previous 24 hours at each visit. Analgesic response was classified per Farrar\u2019s criteria as non-responders (no improvement or worsening), poor responders (&lt;30%\u2009PI reduction) or responders (\u226530% reduction). Responders with final API \u22644 were also classified as responders per Corli\u2019s criteria; others were non-responders. Statistical analyses included \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      and Fisher\u2019s exact tests, t-tests, Mann-Whitney tests, linear mixed models and logistic regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PI did not differ significantly between sexes. However, in the fentanyl group, dose increased over time differently between sexes (sex-by-time interaction: p=0.0026). Opioid switching from buprenorphine was more often due to inadequate pain control in men, and due to uncontrollable ADRs in women. Among patients with colorectal cancer, women showed greater pain reduction of the worst pain according to Farrar\u2019s criteria (91.3% vs 61.8%, p=0.022). ADRs incidence was higher in women than in men for transdermal buprenorphine (93.2% vs 77.9%, p=0.016). Higher baseline emotional tension was negatively associated with analgesic response (OR 0.64, 95% CI 0.41 to 1.00). Other efficacy and safety outcomes were not statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall pain reduction did not differ by sex; however, men and women exhibited distinct patterns in dose escalation, opioid switching and ADR profiles. Accounting for sex differences may support more tailored and effective opioid selection in cancer pain management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01809106\">NCT01809106<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjonc-2025-001024","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T16:05:29Z","timestamp":1775145929000},"page":"e001024","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Analgesic efficacy in women and men with cancer pain, treated with strong opioids: are there differences?"],"prefix":"10.1136","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct01809106","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01809106","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01809106","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Oscar","family":"Corli","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Istituto Di Ricerche Farmacologiche Mario Negri, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6270-6559","authenticated-orcid":false,"given":"Lorenzo","family":"Caldirola","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Istituto Di Ricerche Farmacologiche Mario Negri, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Galli","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Istituto Di Ricerche Farmacologiche Mario Negri, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valter","family":"Torri","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Istituto Di Ricerche Farmacologiche Mario Negri, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Garattini","sequence":"additional","affiliation":[{"name":"Presidence, Istituto Di Ricerche Farmacologiche Mario Negri, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliana","family":"Rulli","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Istituto Di Ricerche Farmacologiche Mario Negri, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Apolone","sequence":"additional","affiliation":[{"name":"Scientific Director, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy"},{"name":"Organization of European Cancer Institutes, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"2026040209052097000_5.1.e001024.1","unstructured":"Mogil JS , Pogatzki-Zahn EM , Roche M , et al . Biological mechanisms underlying sex differences in pain. Sex and gender disparities in pain. IASP; 2024:1\u20133."},{"key":"2026040209052097000_5.1.e001024.2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/j.pain.0000000000000389","article-title":"Sex differences in pain: a tale of two immune cells","volume":"157 Suppl 1","author":"Mapplebeck","year":"2016","journal-title":"Pain"},{"key":"2026040209052097000_5.1.e001024.3","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.23831"},{"key":"2026040209052097000_5.1.e001024.4","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002215"},{"key":"2026040209052097000_5.1.e001024.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-020-0310-6"},{"key":"2026040209052097000_5.1.e001024.6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1248\/bpb.b20-01028","article-title":"Construction of a Risk Prediction Model of Extended Release Oxycodone Tablet-Induced Nausea and Clarification of Predictive Factors","volume":"44","author":"Kumai","year":"2021","journal-title":"Biol Pharm Bull"},{"key":"2026040209052097000_5.1.e001024.7","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1007\/s13346-023-01305-y","article-title":"An individualized digital twin of a patient for transdermal fentanyl therapy for chronic pain management","volume":"13","author":"Bahrami","year":"2023","journal-title":"Drug Deliv Transl Res"},{"key":"2026040209052097000_5.1.e001024.8","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jgo.2019.01.005","article-title":"Prevalence of pain in patients with cancer aged 70\u202fyears or older: A prospective observational study","volume":"10","author":"Brunello","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"2026040209052097000_5.1.e001024.9","unstructured":"World Health Organizationx . Cancer pain relief. 2nd edn. Geneva: World Health Organization, 1996."},{"key":"2026040209052097000_5.1.e001024.10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw097"},{"key":"2026040209052097000_5.1.e001024.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70040-2"},{"key":"2026040209052097000_5.1.e001024.12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/oxfordjournals.annonc.a058263","article-title":"A therapy impact questionnaire for quality-of-life assessment in advanced cancer research","volume":"3","author":"Tamburini","year":"1992","journal-title":"Ann Oncol"},{"key":"2026040209052097000_5.1.e001024.13","doi-asserted-by":"publisher","DOI":"10.1002\/j.1532-2149.2012.00257.x"},{"key":"2026040209052097000_5.1.e001024.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(00)00339-0"},{"key":"2026040209052097000_5.1.e001024.15","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-020-00957-5"},{"key":"2026040209052097000_5.1.e001024.16","doi-asserted-by":"crossref","DOI":"10.1111\/gbb.12829","article-title":"Sex-specific role of the circadian transcription factor NPAS2 in opioid tolerance, withdrawal and analgesia","volume":"21","author":"Puig","year":"2022","journal-title":"Genes Brain Behav"},{"key":"2026040209052097000_5.1.e001024.17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41386-021-01200-5","article-title":"Fentanyl-induced hyperalgesia and analgesic tolerance in male rats: common underlying mechanisms and prevention by a polyamine deficient diet","volume":"47","author":"Laboureyras","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"2026040209052097000_5.1.e001024.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0280212","article-title":"Predicting tolerability of high-dose fentanyl buccal tablets in cancer patients","volume":"18","author":"Kwon","year":"2023","journal-title":"PLoS ONE"},{"key":"2026040209052097000_5.1.e001024.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.10.012"},{"key":"2026040209052097000_5.1.e001024.20","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2021.1946368","article-title":"Chronic opioid use modulates human enteric microbiota and intestinal barrier integrity","volume":"13","author":"Cruz-Lebr\u00f3n","year":"2021","journal-title":"Gut Microbes"},{"key":"2026040209052097000_5.1.e001024.21","doi-asserted-by":"crossref","DOI":"10.3390\/medicina61071172","article-title":"Sex-Related Differences in Chronic Pain: A Narrative Review by a Multidisciplinary Task Force","volume":"61","author":"Marchesini","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"2026040209052097000_5.1.e001024.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104522"},{"key":"2026040209052097000_5.1.e001024.23","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12060907","article-title":"Sex-Related Differences in Pharmacological Response to CNS Drugs: A Narrative Review","volume":"12","author":"Romanescu","year":"2022","journal-title":"J Pers Med"},{"key":"2026040209052097000_5.1.e001024.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchemneu.2008.08.001"},{"key":"2026040209052097000_5.1.e001024.25","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.2147\/JPR.S94650","article-title":"Gender, genetics and analgesia: understanding the differences in response to pain relief","volume":"11","author":"Packiasabapathy","year":"2018","journal-title":"J Pain Res"},{"key":"2026040209052097000_5.1.e001024.26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/pm\/pny040","article-title":"Hormone Replacement Therapy and Opioid Tapering for Opioid-Induced Hypogonadism Among Patients with Chronic Noncancer Pain: A Systematic Review","volume":"20","author":"AminiLari","year":"2019","journal-title":"Pain Med"},{"key":"2026040209052097000_5.1.e001024.27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.coemr.2019.04.007","article-title":"Opioid-induced androgen deficiency (OPIAD): prevalence, consequence, and efficacy of testosterone replacement","volume":"6","author":"Ho","year":"2019","journal-title":"Curr Opin Endocrinol Metab Res"},{"key":"2026040209052097000_5.1.e001024.28","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2017.04.170112"},{"key":"2026040209052097000_5.1.e001024.29","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000763"},{"key":"2026040209052097000_5.1.e001024.30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamapsychiatry.2020.3554","article-title":"Prescription Opioid Use and Risk for Major Depressive Disorder and Anxiety and Stress-Related Disorders: A Multivariable Mendelian Randomization Analysis","volume":"78","author":"Rosoff","year":"2021","journal-title":"JAMA Psychiatry"}],"container-title":["BMJ Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjonc-2025-001024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T16:05:32Z","timestamp":1775145932000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjoncology.bmj.com\/lookup\/doi\/10.1136\/bmjonc-2025-001024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,4,2]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjonc-2025-001024"],"URL":"https:\/\/doi.org\/10.1136\/bmjonc-2025-001024","relation":{},"ISSN":["2752-7948"],"issn-type":[{"value":"2752-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}